iCo Therapeutics Inc. (ICO: TSX-V, ICOTF:OTCQX) is a biotechnology company with an efficient approach to drug development and therapies targeting underserved medical indications. Employing a no research, development only (NRDO) approach to reduce drug discovery risks and requirements, iCo acquires promising candidates with identified targets and demonstrations of systemic safety, including novel reformulations of off‐patent drugs. This also provides a repurposing aspect to iCo’s approach, and candidates are developed for use in other or expanded indications with significant market potential.  Management strength is supported by an impressive group of Directors and Advisors.